| Literature DB >> 17254341 |
Signe Borgquist1, Elisabet Wirfält, Karin Jirström, Lola Anagnostaki, Bo Gullberg, Göran Berglund, Jonas Manjer, Göran Landberg.
Abstract
BACKGROUND: The general lack of clear associations between diet and breast cancer in epidemiological studies may partly be explained by the fact that breast cancer is a heterogeneous disease that may have disparate genetic associations and different aetiological bases.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17254341 PMCID: PMC1851395 DOI: 10.1186/bcr1644
Source DB: PubMed Journal: Breast Cancer Res ISSN: 1465-5411 Impact factor: 6.466
Description of the study population
| Factor (number of individuals for whom information was available) | Incident breast cancer ( |
| Age at baseline (years; 440) | 57.2 (7.1) |
| Education (439) | 70 |
| O-level college | 6 |
| A-level college university | 24 |
| Type of occupation (431) | |
| Manual worker | 34 |
| Nonmanual worker | 59 |
| Employer/self-employed | 7 |
| Married/cohabiting (440) | |
| No | 34 |
| Yes | 66 |
| Age at menarche (years; 440) | |
| ≤12 | 22 |
| >12 to <15 | 52 |
| ≥15 | 26 |
| Parity (number of children; 426) | |
| 0 | 13 |
| 1 | 20 |
| 2 | 44 |
| 3 | 18 |
| ≥4 | 5 |
| Age at first childbirth (years; 440) | |
| Nullipara | 13 |
| ≤20 | 17 |
| >20 to ≤25 | 34 |
| >25 to ≤30 | 26 |
| >30 | 10 |
| Menopausal status (440) | |
| Premenopausal | 25 |
| Perimenopausal | 7 |
| Postmenopausal | 68 |
| Exposure to OC (439) | |
| Never | 49 |
| Ever | 51 |
| Current use of HRT (440) | |
| No | 71 |
| Yes | 29 |
| Body mass index (kg/m2; 440) | 25.5 (4.1) |
| Alcohol consumption (440) | |
| Nothing last year (teetotaller) | 11 |
| Something last year (not last month) | 11 |
| Something last month | 78 |
| Smoking (440) | |
| Never | 40 |
| Current | 30 |
| Ex | 30 |
Values are expressed as percentage or as mean (standard deviation). HRT, hormone replacement therapy; OC, oral contraceptives.
Associations between tumour type, grade, ER, cyclin D1, cyclin E, p27 and proliferation (Ki67)
| Tumour grading | Nucleus grade | ER | Cyclin D1 | Cyclin E | p27 | Ki67 | |
| Tumour typea | (<0.001**) | (<0.001**) | (0.01*) | (0.11) | (0.10) | (0.67) | (0.009**) |
| Tumour grading | 1 (-) | 0.789 (<0.001**) | -0.374 (<0.001**) | 0.082 (0.155) | 0.339 (<0.001**) | -0.271 (<0.001**) | 0.530 (<0.001**) |
| Nucleus grade | 1 (-) | -0.369 (<0.001** | 0.050 (0.391) | 0.323 (<0.001**) | -0.188 (0.001) | 0.448 (<0.001**) | |
| ER | 1 (-) | 0.154 (0.007**) | -0.540 (<0.001**) | 0.291 (<0.001**) | -0.282 (<0.001**) | ||
| Cyclin D1 | 1 (-) | 0.024 (0.674) | 0.262 (<0.001**) | 0.288 (<0.001**) | |||
| Cyclin E | 1 (-) | -0.094 (0.099) | 0.395 (<0.001**) | ||||
| p27 | 1 (-) | -0.211 (<0.001**) | |||||
| Ki67 | 1 (-) |
P values are given in parentheses. aFor tumour type (ductal, lobular, tubular), the χ2 test was used. Otherwise, Pearson's correlation test was used. *P < 0.05, **P < 0.01. ER, oestrogen receptor.
Mean values for anthropometric measurements in specific subgroups of breast cancer
| Height (m) | BMI (kg/m2) | Hip (m) | Waist (m) | Body fat (%) | ||
| PAD | ||||||
| | 0.98 | 0.69 | 0.19 | 0.16 | 0.82 | |
| Ductal | 239 | 1.64 | 25 | 0.98 | 0.78 | 31 |
| Lobular | 72 | 1.64 | 25 | 0.98 | 0.77 | 30 |
| Tubular | 22 | 1.64 | 25 | 0.95 | 0.75 | 31 |
| Othersa | 13 | - | - | - | - | - |
| Grade | ||||||
| | 0.01* | 0.03* | 0.009** | 0.18 | 0.06 | |
| Grade 1 | 95 | 1.66 | 24 | 0.96 | 0.76 | 30 |
| Grade 2 | 164 | 1.64 | 26 | 0.99 | 0.79 | 31 |
| Grade 3 | 85 | 1.64 | 25 | 0.98 | 0.78 | 31 |
| Nucleus grade | ||||||
| | 0.08 | 0.11 | 0.02* | 0.27 | 0.19 | |
| Nuclear grade 1 | 52 | 1.65 | 24 | 0.95 | 0.76 | 30 |
| Nuclear grade 2 | 176 | 1.63 | 25 | 0.99 | 0.78 | 30 |
| Nuclear grade 3 | 115 | 1.63 | 26 | 0.98 | 0.78 | 31 |
| ER | ||||||
| | 0.62 | 0.33 | 0.14 | 0.41 | 0.39 | |
| 0–1% | 27 | 1.64 | 25 | 0.96 | 0.76 | 30 |
| 2–10% | 4 | 1.63 | 27 | 1.02 | 0.78 | 32 |
| 11–50% | 12 | 1.62 | 27 | 1.03 | 0.82 | 33 |
| 51–100% | 277 | 1.64 | 25 | 0.98 | 0.78 | 30 |
| Cyclin D1 | ||||||
| | 0.84 | 0.16 | 0.13 | 0.35 | 0.46 | |
| 0–1% | 208 | 1.64 | 25 | 0.98 | 0.78 | 30 |
| 2–10% | 64 | 1.64 | 26 | 0.99 | 0.79 | 31 |
| 11–50% | 27 | 1.64 | 25 | 0.97 | 0.76 | 31 |
| 51–100% | 12 | 1.63 | 24 | 0.93 | 0.74 | 30 |
| Cyclin E | ||||||
| | 0.002** | 0.75 | 0.81 | 0.82 | 0.97 | |
| 0–1% | 251 | 165 | 25 | 0.98 | 0.78 | 30 |
| 2–10% | 40 | 162 | 25 | 0.98 | 0.77 | 31 |
| 11–50% | 16 | 161 | 26 | 0.98 | 0.79 | 31 |
| 51–100% | 10 | 163 | 25 | 0.95 | 0.75 | 31 |
| p27 | ||||||
| | 0.19 | 0.39 | 0.16 | 0.10 | 0.08 | |
| 0–1% | 90 | 165 | 25 | 0.98 | 0.78 | 31 |
| 2–10% | 50 | 164 | 26 | 1.00 | 0.80 | 32 |
| 11–50% | 71 | 163 | 25 | 0.96 | 0.76 | 30 |
| 51–100% | 102 | 164 | 25 | 0.97 | 0.77 | 30 |
| Ki67 | ||||||
| | 0.90 | 0.31 | 0.17 | 0.59 | 0.10 | |
| 0–1% | 130 | 164 | 25 | 0.97 | 0.77 | 30 |
| 2–10% | 93 | 164 | 26 | 0.99 | 0.79 | 31 |
| 11–50% | 57 | 165 | 25 | 0.97 | 0.77 | 30 |
| 51–100% | 33 | 164 | 26 | 0.97 | 0.77 | 31 |
aMucinous, medullary, and intracystic breast tumours were not included in statistical analyses because of their small number. *P < 0.05; **P < 0.01. ER, oestrogen receptor; PAD, pathological anatomical diagnosis.
Means of intake of energy, macronutrients, and fatty acids in relation to specific subgroups of breast cancer
| Energy (Joule/day) | Total fat (g/day) | Total carbohydrates (g/day) | Total protein (g/day) | Total alcohol (g/day) | SFA (g/day) | MUFA (g/day) | PUFA (g/day) | |
| PAD | ||||||||
| | 0.82 | 0.56 | 0.84 | 0.94 | 0.12 | 0.86 | 0.34 | 0.27 |
| Ductal | 1955 | 82 | 212 | 76 | 1.0 | 35 | 29 | 13 |
| Lobular | 1929 | 79 | 210 | 75 | 1.9 | 34 | 27 | 12 |
| Tubular | 2006 | 82 | 219 | 77 | 2.6 | 34 | 28 | 13 |
| Othersa | ||||||||
| Grade | ||||||||
| | 0.09 | 0.20 | 0.39 | 0.02* | 0.28 | 0.16 | 0.34 | 0.40 |
| 1 | 2002 | 83 | 216 | 78 | 1.7 | 35 | 29 | 13 |
| 2 | 1966 | 82 | 212 | 77 | 1.3 | 35 | 29 | 13 |
| 3 | 1852 | 77 | 204 | 71 | 0.9 | 32 | 27 | 12 |
| Nucleus grade | ||||||||
| | 0.02* | 0.07 | 0.06 | 0.02* | 0.10 | 0.04* | 0.16 | 0.48 |
| 1 | 2012 | 83 | 217 | 78 | 2.5 | 36 | 29 | 13 |
| 2 | 2002 | 84 | 217 | 78 | 1.1 | 36 | 29 | 13 |
| 3 | 1846 | 77 | 201 | 72 | 1.0 | 32 | 27 | 12 |
| ER | ||||||||
| | 0.90 | 0.75 | 0.77 | 0.80 | 0.80 | 0.73 | 0.55 | 0.98 |
| 0 | 1955 | 81 | 219 | 72 | 0.9 | 33 | 29 | 13 |
| 1 | 1794 | 74 | 188 | 76 | 3.7 | 31 | 25 | 12 |
| 2 | 1895 | 75 | 214 | 77 | 1.3 | 31 | 25 | 13 |
| 3 | 1954 | 82 | 211 | 76 | 1.3 | 35 | 29 | 13 |
| Cyclin D1 | ||||||||
| | 0.11 | 0.06 | 0.37 | 0.12 | 0.56 | 0.02* | 0.046* | 0.47 |
| 0 | 1968 | 82 | 213 | 77 | 1.3 | 35 | 29 | 13 |
| 1 | 1943 | 82 | 208 | 74 | 1.4 | 34 | 29 | 13 |
| 2 | 1891 | 80 | 206 | 71 | 0.6 | 36 | 28 | 12 |
| 3 | 1651 | 64 | 185 | 67 | 0.6 | 25 | 22 | 11 |
| Cyclin E | ||||||||
| | 0.10 | 0.03* | 0.43 | 0.25 | 0.40 | 0.04* | 0.05 | 0.14 |
| 0 | 1963 | 82 | 212 | 76 | 1.4 | 35 | 29 | 13 |
| 1 | 1786 | 72 | 198 | 71 | 0.6 | 30 | 26 | 12 |
| 2 | 2016 | 83 | 222 | 79 | 1.6 | 34 | 30 | 13 |
| 3 | 2139 | 98 | 222 | 81 | 1.0 | 42 | 34 | 16 |
| p27 | ||||||||
| | 0.49 | 0.93 | 0.12 | 0.43 | 0.78 | 0.98 | 0.96 | 0.69 |
| 0 | 1970 | 81 | 216 | 75 | 1.3 | 34 | 29 | 13 |
| 1 | 1947 | 81 | 217 | 75 | 0.8 | 34 | 28 | 13 |
| 2 | 1876 | 80 | 197 | 73 | 1.3 | 34 | 28 | 12 |
| 3 | 1988 | 83 | 214 | 78 | 1.3 | 35 | 29 | 13 |
| Ki67 | ||||||||
| | 0.16 | 0.02* | 0.78 | 0.40 | 0.27 | 0.02* | 0.02* | 0.02* |
| 0 | 1970 | 83 | 210 | 77 | 1.6 | 35 | 29 | 13 |
| 1 | 2002 | 85 | 214 | 77 | 1.4 | 36 | 30 | 13 |
| 2 | 1835 | 72 | 206 | 72 | 0.7 | 30 | 25 | 12 |
| 3 | 1872 | 79 | 204 | 73 | 0.8 | 35 | 28 | 11 |
aMucinous, medullary and intracystic breast tumours were not included in statistical analyses because of their small number. *P < 0.05; **P < 0.01. ER, oestrogen receptor; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; PAD, pathological anatomical diagnosis; SFA, saturated fatty acids.
Means of intake of energy, macronutrients, and fatty acids in relation to specific subgroups of breast cancer
| Energy (Joules/day) | Total fat (g/day) | Energy-adjusted fat (g/day) | SFA (g/day) | Energy-adjusted SFA (g/day) | MUFA (g/day) | Energy-adjusted MUFA (g/day) | PUFA (g/day) | Energy-adjusted PUFA (g/day) | |
| Cyclin D1a | |||||||||
| | 0.02* | 0.007** | 0.16 | 0.002* | 0.04* | 0.006** | 0.13 | 0.32 | 0.31 |
| Low | 1957 | 82 | 81 | 35 | 34 | 29 | 28 | 13 | 13 |
| High | 1652 | 63 | 76 | 25 | 30 | 22 | 26 | 11 | 13 |
| Cyclin Eb | |||||||||
| | 0.26 | 0.07 | 0.09 | 0.09 | 0.18 | 0.08 | 0.12 | 0.07 | 0.15 |
| Low | 1937 | 80 | 81 | 34 | 34 | 28 | 28 | 13 | 13 |
| High | 2123 | 97 | 88 | 42 | 38 | 34 | 31 | 15 | 14 |
| Ki67c | |||||||||
| | 0.029* | 0.004** | 0.048* | 0.019* | 0.315 | 0.004** | 0.058 | 0.003** | 0.053 |
| Low | 1984 | 84 | 82 | 35 | 35 | 29 | 29 | 13 | 13 |
| High | 1850 | 75 | 79 | 32 | 34 | 26 | 28 | 12 | 12 |
All analyses are adjusted for age, diet assistant, period, method version and changed dietary habits. Energy adjustment is applied where stated. aCyclin D1 overexpression with nucleus fraction ≥50%. bCyclin E overexpression with nucleus fraction ≥50%. cHigh proliferation index with nuclear fraction ≥10. *P < 0.05; **P < 0.01. MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; SFA, saturated fatty acids.